Karo Healthcare expands its presence in Italy with the acquisition of the rights to Proctosedyl® from Bayer
Karo Healthcare AB (‘Karo’) announces the acquisition of the rights to the OTC brand Proctosedyl from Bayer. The transaction transfers global dossier ownership to the OTC pharmaceutical Proctosedyl, and exclusive license to the Proctosedyl trademark in Italy, from Bayer to Karo. This acquisition amplifies Karo’s presence in Italy while aligning with Karo’s M&A strategy of focusing on brands with strong equity in categories associated with discomfort and embarrassment. Proctosedyl is a leading brand in Italy for the treatment of hemorrhoids. The acquisition strengthens and